WEBULL

Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema

Simply Wall St · 1d ago

Pharvaris (NasdaqGS:PHVS) just cleared a major clinical hurdle, with its RAPIDe-3 Phase 3 trial of oral deucrictibant hitting all primary and secondary endpoints in hereditary angioedema. The company intends to use these data as the basis for 2026 approval filings.

See our latest analysis for Pharvaris.

Even with the recent pullback, including a 1 day share price return of minus 4.6 percent and minus 6.9 percent over 7 days, Pharvaris still shows building momentum with a 30 day share price return above 20 percent and a three year total shareholder return above 200 percent.

If deucrictibant’s progress has you watching rare disease names more closely, it could be worth scanning other specialist healthcare stocks that might be setting up for their next catalyst.

With shares still trading at a steep discount to consensus targets despite strong late stage data and a multiyear rally, is Pharvaris quietly undervalued, or is the market already baking in years of future growth?

Price to Book of 4.7x: Is it justified?

On a price to book basis, Pharvaris looks expensive at the last close of $26.42, trading well above both industry and peer benchmarks.

The price to book ratio compares the company’s market value to its net assets, a common yardstick for development stage biotechs with little or no revenue. For Pharvaris, a 4.7x multiple implies investors are paying a sizeable premium over the company’s current balance sheet value, effectively front loading expectations for future commercial success from deucrictibant.

However, this premium stands out. Pharvaris is described as expensive versus the broader US pharmaceuticals industry, where the average price to book is just 2.5x, and it also screens as expensive against a 3.5x peer average. That gap suggests the market is assigning Pharvaris a richer valuation than many similar names, with the multiple positioned well above levels the industry typically supports.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book of 4.7x (OVERVALUED)

However, setbacks in Phase 3 execution or slower than expected HAE adoption could quickly compress Pharvaris’s premium multiple and stall its recent momentum.

Find out about the key risks to this Pharvaris narrative.

Another Lens on Value

Our DCF model paints a very different picture, suggesting Pharvaris is trading well above an estimated fair value of about $9.79 per share. If that cash flow view is closer to reality than today’s growth story pricing, how much downside are investors really underwriting?

Look into how the SWS DCF model arrives at its fair value.

PHVS Discounted Cash Flow as at Dec 2025
PHVS Discounted Cash Flow as at Dec 2025

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pharvaris for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 906 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Pharvaris Narrative

If you see the numbers differently or want to stress test your own assumptions, you can build a personalised Pharvaris storyline in just a few minutes: Do it your way.

A great starting point for your Pharvaris research is our analysis highlighting 3 important warning signs that could impact your investment decision.

Ready for more high conviction ideas?

Before you move on, lock in your next watchlist candidates with the Simply Wall St Screener, so you never leave potential winners sitting unseen.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.